NPS Pharmaceuticals

Gastro-intestinals

NPS Pharmaceuticals

USA-based NPS Pharmaceuticals (Nasdaq: NPSP) is a biopharmaceutical company.

USA-based NPS Pharmaceuticals (Nasdaq: NPSP) is a biopharmaceutical company.

The company'’s lead product, Gattex (teduglutide [rDNA origin]) for injection is approved for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS is also developing Natpara (rhPTH[1-84]) for the treatment of adult hypoparathyroidism and expects to submit its Biologic License Application (BLA) to the FDA in the second half of 2013.

NPS's earlier-stage pipeline includes NPSP795, a calcilytic compound with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa HakkoKirin.


Latest Articles

Latest News

Who's Who

Company Spotlight

ImmunoGen

ImmunoGen

Back to top